Dr. Asnat Raziel

My articles

My articles

Early response to CagriSema: 5% by week 8 led to 25% by week 68

Early response to CagriSema: the new data

An early response to CagriSema may hint at what comes next. In a new analysis, two thirds of patients lost 5% or more by week 8. That group went on to lose an average of 25.4% after 68 weeks. Researchers shared the data at ObesityWeek in Washington. They also presented lower-dose results and data on physical function.

CagriSema is an investigational once-weekly injection from Novo Nordisk. It combines semaglutide, the active ingredient in Wegovy, with cagrilintide, a long-acting version of the hormone amylin. No regulator has approved it yet. The FDA expects to decide by year end.

What the new analysis looked at

The analysis draws on the REDEFINE 1 trial. There, participants received the full dose of 2.4 mg of each component. The researchers split patients into two groups. “Early responders” lost at least 5% of their weight by week 8. “Delayed responders” did not reach that threshold in time.

According to Medscape’s report, 1,367 of 2,016 patients, or 67.8%, were early responders. By week 68, they had lost an average of 25.4% of their body weight. Delayed responders, by contrast, lost an average of 17.8%.

An early response to CagriSema is not destiny

To me, the second number matters most. Even people who did not lose 5% in the first two months reached an average loss of 17.8%. That is a very meaningful result. So a slow start is no reason to give up.

Dr. W. Timothy Garvey, who presented the analysis, stressed that it only generates hypotheses. In his words, it should not change clinical decisions. In other words, patients should not stop treatment just because weight loss at week 8 is under 5%. I wrote about how patients differ in my article on response to weight loss drugs.

Lower doses: the full results

The meeting also featured the full results of the REDEFINE 9 trial. The Lancet Diabetes & Endocrinology published it at the same time. It enrolled 309 adults with obesity or overweight and without diabetes. They received 1.7 mg or 1.0 mg of each component, or placebo, for 68 weeks.

Under the efficacy estimand, average weight loss was 20.7% with 1.7 mg. With 1.0 mg it was 21.0%, compared with 2.0% on placebo. What’s more, 95.1% and 96.3% of patients lost at least 5% of their weight, compared with 33.4% on placebo.

Two numbers for the same trial

The efficacy estimand looks at what happens when patients stay on treatment as planned. The treatment regimen estimand, on the other hand, includes everyone, even those who stopped. By that method, weight loss was 19.4% and 18.6%, compared with 4.6% on placebo.

When you read a headline about a new drug, check which method the researchers used. The higher number describes people who stick with treatment. The lower one is closer to the picture for all patients.

Early response to CagriSema in physical function too

Another REDEFINE 1 analysis looked at how patients feel day to day. The researchers used a validated questionnaire on how weight affects quality of life. At week 68, 73.1% of patients on CagriSema reported a meaningful improvement in physical function. On placebo, the figure was 49.1%.

The gap between the groups appeared as early as week 8 and held through the end. Dr. Domenica Rubino, one of the authors, explained that patients care most about moving comfortably and taking part in life. I see the goal of treatment the same way. It is not just a number, but an active life.

Safety and side effects

According to Novo Nordisk, the trials showed no new safety signals. Side effects were mainly gastrointestinal, as in earlier trials. In REDEFINE 9, most side effects were mild to moderate, and there were no deaths.

Early response to CagriSema: infographic on REDEFINE 1 and REDEFINE 9

What this means for you

First, the start matters, but it does not decide everything. People who lose weight quickly in the first two months reach an especially large result on average. Still, people who start slowly can also reach meaningful weight loss.

Second, a lower dose may be enough for some patients. That matters for anyone dealing with nausea or other side effects. Finally, we also measure success in function: walking, climbing stairs and feeling energetic. I covered this drug class in my article on amylin-based drugs. I also wrote about the weight loss plateau.

The bottom line

The data from the meeting show that CagriSema works at lower doses and also improves everyday function. An early response to CagriSema may help estimate what lies ahead. Still, it should not drive a decision to stop. Ultimately, doctor and patient should make the decision together, with close follow-up.

This article provides general information and is not a substitute for personal medical advice.

References

Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9)

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

Lower CagriSema Doses Beat Placebo; Early Response Matters

Novo Nordisk funded the trials.

Early response to CagriSema: two young women cycling up a coastal road and high-fiving at the top of the climb

Dr. Asnat Raziel